ArticleLife (Basel, Switzerland)2023

Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report.

Roger Kai-Cheong NganPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.